| Literature DB >> 28474729 |
Liangying Yin, Zhengxing Huang1, Wei Dong, Chunhua He, Huilong Duan.
Abstract
OBJECTIVES: Medical behaviors are playing significant roles in the delivery of high quality and cost-effective health services. Timely discovery of changing frequencies of medical behaviors is beneficial for the improvement of health services. The main objective of this work is to discover the changing trends of medical behaviors over time.Entities:
Keywords: Changing pattern detection; Electronic Medical Records; Latent Dirichlet allocation; medical behavior
Mesh:
Year: 2017 PMID: 28474729 PMCID: PMC5435874 DOI: 10.3414/ME16-01-0047
Source DB: PubMed Journal: Methods Inf Med ISSN: 0026-1270 Impact factor: 2.176
Figure 1A detailed example of medical behaviors in a patient’s treatment process.
Figure 2Detailed steps of the proposed approach.
Figure 3Graphical model reprentation of LDA [7].
Definitions of parameters.
| Parameter | Definition |
|---|---|
| Prior parameter of Dirichlet distribution | |
| Prior parameter of Dirichlet distribution | |
| Treatment pattern numbers | |
| EMR of a particular patient sample | |
| A specific treatment pattern | |
| Distribution of each σ | |
| Occurring probability of a treatment pattern | |
| Distribution of each treatment pattern | |
| Occurring probability of each feaure-value in a treatment pattern | |
| Occurring probability of each treatment intervention in a treatment pattern | |
| Daily occurring probability of a treatment intervention in treatment pattern | |
| The largest length of stay of yearly collection of EMRs | |
| Number of feaure-value pairs/intervention-occurring time pairs in treatment pattern | |
| Summing results of α over | |
| Summing results of β over M times |
Figure 4Three pairs of conversely changing patterns of feature-value pairs. (a) Growing and declining pattern, (b) Up-down and down-up pattern, and (c) Steady and jumping pattern.
Figure 5Changing patterns of implementation time of treatment interventions. (a) Early-implemented, (b) Steady-implemented, and (c) Delay-implemented.
Figure 6Patient data extraction from EMR system.
Demographic attributes of the experimental dataset.
| Year | Traces | Male | Female | Average age | Average stay | Feature types | Intervention types |
|---|---|---|---|---|---|---|---|
| 2004 | 657 | 517 | 140 | 64.9 | 15.87 | 106 | 280 |
| 2005 | 1022 | 775 | 247 | 63.1 | 11.6 | 123 | 303 |
| 2006 | 1268 | 925 | 343 | 65.3 | 11.34 | 135 | 317 |
| 2007 | 1445 | 1040 | 405 | 62.6 | 9.04 | 136 | 349 |
| 2008 | 1694 | 1214 | 480 | 62.2 | 9.25 | 141 | 350 |
| 2009 | 1541 | 1092 | 449 | 63.0 | 9.03 | 135 | 333 |
| 2010 | 1003 | 707 | 296 | 61.6 | 7.5 | 83 | 307 |
| 2011 | 1470 | 1056 | 414 | 61.8 | 6.53 | 97 | 344 |
| 2012 | 1670 | 1167 | 503 | 61.8 | 7.14 | 93 | 370 |
| 2013 | 382 | 252 | 130 | 60.9 | 7.12 | 66 | 231 |
Changing patterns of medical behaviors detected from the experimental dataset.
| Risk levels | Patient features | Treatment interventions | ||||
|---|---|---|---|---|---|---|
| low | medium | high | low | medium | high | |
| 8 | 17 | 15 | 23 | 25 | 24 | |
| 8 | 17 | 20 | 22 | 24 | 32 | |
| 5 | 0 | 0 | 10 | 9 | 11 | |
| 3 | 8 | 8 | 3 | 14 | 7 | |
| 6 | 0 | 0 | 3 | 5 | 2 | |
| 2 | 8 | 10 | 3 | 7 | 10 | |
Changing trends of execution time for treatment interventions.
| Risk levels | Steady-implemented | Early-implemented | Delay-implemented |
|---|---|---|---|
| 48 | 13 | 3 | |
| 2 | 78 | 4 | |
| 0 | 84 | 2 |
Changing patient feature-value pairs detected from the experimental dataset with respect to different risk levels.
| Total cholesterol :L, Atherosclerosis :True, Quantitative determination of Isoenzyme of creatine kinase :N, Glucose :L, Mean platelet volume :L, Creatine kinase :L, ProBNP :N, Triglycerides :L | |
| Gender:Male, Creatine kinase:N, Triglycerides:H, Unsaturated iron binding capacity:L, Hypertension:True, Qualitative urine test:H, TIBC:L, Total cholesterol:H | |
| Sodium:L, Creatinine:L, Age, Attack of angina:True, Lactate dehydrogenase:L | |
| High-density lipoprotein cholesterol:H, Low-density lipoprotein cholesterol:H, Isoenzyme of creatine kinase:N | |
| Hemoglobin:L, Potassium:H, Platelet:L, Troponin T:N, Potassium:L, Low-density lipoprotein cholesterol:N | |
| Mean corpuscular hemoglobin :L, Hemoglobin :L | |
| Attack of angina:True, After PCI:True, Cardiac insufficiency:True, Atherosclerosis:True, TEG-MA:L, Age, Acute coronary syndrome:True, Myocardial bridge:True, TEG-E:L, High-sensitivity C-reactive protein:N, TEG-K, Platelet hematocrit, Platelet volume distribution width, History of coronary heart disease:True, TEG-R:L, After CABG:True, U-mALb/Ucr:N | |
| Hypertension:True, Diabetes:True, Prostate disease:True, Hyperlipidemia:True, Renal insufficiency:True, Tumor:True, Cerebral infarction:True, Artery stenosis:True, Hyperlipidemia:True, Pulmonary disease:True, Sick sinus syndrome:True, Ischemic cardiomyopathy:True, Insufficient blood supply:True, Anemia:True, Abnormal glucose tolerance:True, Bleeding:True, Renal cyst:True | |
| Isoenzyme of creatine kinase:N, Unsaturated iron binding capacity:L, Troponin T:N, Fecal transferrin: Negative Quantitative determination of Isoenzyme of creatine kinase:N, 2 hours glucose tolerance test, ProBNP:N, Serum ferritin:L | |
| Troponin T:H, Cardiac arrhythmia:True, Fasting serum insulin, Qualitative urine test:N, Urinary potassium:L, Platelet aggregation:L, Urine creatinine:L, Cardiac enlargement:True | |
| Troponin T:H, Attack of angina:True, After PCI:True, Atherosclerosis:True, Platelet volume distribution width, Platelet hematocrit, TEG-K, History of coronary heart disease:True, Acute coronary syndrome:True, MCHC:L, After CABG:True, 2 hours glucose tolerance test, Low-density lipoprotein cholesterol:N, Urine creatinine:L, Age | |
| Hypertension:True, Cerebral infarction:True, Diabetes:True, Prostate disease:True, Renal insufficiency:True, Tumor:True, Thrombosis:True, Hyperlipidemia:True, Thrombocytopenia:True, Insufficient blood supply:True, Hyperuricemia:True, Ischemic cardiomyopathy:True, Valvular heart disease:True, Sick sinus syndrome:True, Hypokalemia:True, Anemia:True, Artery stenosis:True, Renal cyst:True, Abnormal glucose tolerance:True, Bleeding:True | |
| Quantitative determination of Isoenzyme of creatine kinase:N, Mean platelet volume:H, Creatine kinase:L, Mean platelet volume:L, Isoenzyme of creatine kinase:N, High-sensitive C-reactive protein:N, Troponin T:N, Hematoma:True | |
| Cardiac insufficiency:True, Hyponatremia:True, 2-hour postprandial serum insulin, Cardiac arrhythmia:True, Fasting serum insulin, Plasma renin activity, High-sensitive C-reactive protein:H, Myocardial bridge:True, Serum ferritin:L ProBNP:N | |
Figure 7Changing trends of example feature-value pairs. (a) “ProBNP:N” and “Qualtitive glucose:H” for low risk patients, and (b) “Attack of angina: True” for low risk patients.
Figure 8Average age of patients in the corresponding risk level. (a) Average age of patients in low risk level, (b) Average age of patients in medium risk level, and (c) Average age of patients in high risk level.
Changing treatment interventions detected from the experimental dataset with respect to different risk levels.
| Antiplatelet drugs, Ultrasound, Lipid regulators, 0.9 % sodium chloride injection, Proton pump inhibitors, Coagulation test, Coronary angiography, PTCA, Consultation, Drug exchange, Blood pressure measurement, Glucose regulators, Blood collection, Occult blood test, Radionuclide examination, Peripheral vasodilators, CT, Thyroid function, Puncture, Monitoring of ECG and blood oxygen, Angiotensin receptor blocker, Anesthesia, Diabetes inspection | |
| Antianginal drugs, Blood routine, Biochemical routine, β adrenergic receptor blockers, First-grade nursing, Thrombosis Inspection, Diuretics, Specific diet, Urine routine, Ganmao Qingre, Calcium channel blocker, Maren Runchang, Xinqingning, Blood typing, Angiotensin converting enzyme inhibitors, Oxygen Inhalation, Mucosal protective agents, Transferred, Sedative and antianxiety drugs, Multifunctional monitors, Troponin T, Stool routine | |
| Drugs for cardiovascular diseases, Routine nursing, Skin preparation, Anti-diabetes drugs, Injection methods, Anticoagulant drugs, Discharge, Second-grade nursing, Serum test, Electrolyte regulators | |
| Local anesthetics, Analysis of blood ion, Parenteral nutrition drugs | |
| Glucose injection, Basic care, Vasodilators | |
| ECG, Tumor marker test, X-Ray | |
| 0.9 % sodium chloride injection, Anticoagulant drug, Troponin T, Drug exchange, Urine routine, Consultation, Injection methods, Anesthesia, Antiplatelet drug, Blood collection, Puncture, Blood pressure measurement, Discharge, Intake and output, Basic care, Ganmao Qingre, Coronary angiography, Proton pump inhibitors, Monitoring of ECG and blood oxygen, Renal function regulators, Adjuvant drugs for liver diseases, PTCA, Angiotensin receptor blocker, TEG, Gastrointestinal prokinetic agent, | |
| Antianginal drugs, Thrombosis Inspection, Plasma and plasma substitutes, Electrolyte regulators, Diuretics, Skin test, Specific diet, Sedative and antianxietic drugs, β adrenergic receptor blockers, Digitalis glycosides, Glucose injection, Anti-diabetes drugs, Angiotensin converting enzyme inhibitors, Second-grade nursing, Routine nursing, Transferred, PH balance regulators, Multifunctional monitors, Tuberculosis examination, Vasoactive drugs, β-lactamase inhibitors, Coagulation test, Narcotic analgesics, Vitamins | |
| Biochemical routine, Glucose regulators, Oxygen Inhalation, Blood routine, Skin preparation, Cephalosporins, Lipid regulators, Enema, Stool routine | |
| Analysis of blood ion, Peripheral vasodilators, Calcium regulators, Tumor marker test, CT, Local anesthetics, Parenteral nutrition drugs, Radionuclide examination, Antiarrhythmic drugs, α-adrenergic receptor blockers, Expectorants, Xinqingning, Occult blood test, Glycyrrhizae Mixture | |
| First-grade nursing, Drugs for cardiovascular diseases, ECG, Ultrasound, Seriously ill | |
| Calcium channel blocker, Drugs for bronchitis, Adrenocorticotropic hormone, Drugs for prostate diseases, Sterilized distilled water, X-Ray, Maren Runchang | |
| Biochemical routine, Blood collection, Radionuclide examination, Drug exchange, Analysis of blood ion, CT, Blood pressure measurement, Xinhuang, Gastrointestinal prokinetic agent, Adjuvant drugs for liver diseases, Digitalis glycosides, Diuretics, Proton pump inhibitors, Coagulation test, Antiarrhythmic drugs, Transferred, Puncture, Expectorants, Troponin T, Intake and output, Local anesthetics, Body temperature lowering, X-Ray, Enema | |
| Antianginal drugs, Calcium channel blocker, Glucose injection, Vasodilators, Sedative and antianxietic drugs, β adrenergic receptor blockers, Specific diet, ECG, Drugs for cardiovascular diseases, Thrombosis Inspection, Angiotensin converting enzyme inhibitors, Immunity test, Skin preparation, Second-grade nursing, Skin test, First-grade nursing, Vasoactive drugs, Narcotic analgesics, Multifunctional monitors, PH balance regulators, Adrenocorticotropic hormone, Nitroglycerin membrane, Electrophysiological examination, Maren Runchang, Antiepileptic and anticonvulsant drugs, Antiplatelet drug, Tuberculosis examination, Furacin, Urine routine, Gastrointestinal antispasmodic drugs, Plasma and plasma substitutes, Diabetes inspection | |
| 0.9 % sodium chloride injection, Blood routine, Routine nursing, Glucose regulators, Sterilized distilled water, Oxygen Inhalation, Basic care, Injection methods, Stool routine, Occult blood test, Discharge | |
| Electrolyte regulators, Cerebral circulation regulators, Monitoring of ECG and blood oxygen, Ultrasound, ß-lactamase inhibitors, Penicillins, Intravenous anesthetics | |
| Anticoagulant drug, Glycyrrhizae Mixture | |
| Cephalosporins, Consultation, Lipid regulators, Calcium regulators, Oral care, Antipyretic and analgesic drugs, Vitamins, Anti-diabetes drugs, Blood transfusion, Parenteral nutrition drugs | |
Unperceived changing trends of medical behaviors beyond clinicians’ expectations.
| Hemoglobin:L(down-up), Platelet:L(down-up), Mean corpuscular hemoglobin:L(jumping) | |
| Bleeding:True(declining), Quantitative determination of Isoenzyme of creatine kinase:N(up-down) | |
| High-sensitive C-reactive protein:H(up-down), Hyperlipidemia:True(declining), Renal insufficiency:True(declining) | |
| Analysis of blood ion(up-down), Thyroid function(growing), Tumor marker test(jumping) | |
| Drugs for prostate diseases(jumping), Gastrointestinal prokinetic agent(growing), Ganmao Qingre(growing) | |
| Gastrointestinal prokinetic agent(growing), Xinhuang(growing), Antiplatelet drugs(declining), Skin preparation(declining), Lipid regulators(jumping) | |
Figure 9Changing trends of example treatment behaviors. (a) “stent implantation” and “ACEI” for low-risk patients, (b) “Coagulation examination” and “Thrombosis examination” for low-risk patients, and (c) “Anticoagulant” and “X-ray” for low-risk patients.
Changing trends of execution time for treatment interventions.
| Discharge, Skin preparation, Drug exchange, Injection methods, Coronary angiography, Anesthesia, Transferred, Electrolyte regulators, Ganmao Qingre, PTCA, Local anesthetics, Puncture, Consultation | |
| Multifunctional monitors, CT, Monitoring of ECG and blood oxygen | |
| Antianginal drugs, Specific diet, Drugs for cardiovascular diseases, Routine nursing, Blood routine, Ultrasound, Biochemical routine,β adrenergic receptor blockers, Thrombosis Inspection, Urine routine, Antiplatelet drugs, Stool routine, ECG, Anticoagulant drugs, Calcium channel blocker, Second-grade nursing, First-grade nursing, Serum test, Lipid regulators, Oxygen Inhalation, 0.9 % sodium chloride injection, Blood collection, Basic care, Angiotensin converting enzyme inhibitors, Blood typing, Sedative and antianxiety drugs, Maren Runchang, Glucose regulators, Anti-diabetes drugs, Vasodilators, Tumor marker test, Blood pressure measurement, X-Ray, Mucosal protective agents, Coagulation test, Occult blood test, Analysis of blood ion, Peripheral vasodilators, Radionuclide examination, Thyroid function, Xinqingning, Diuretics, Troponin T, Angiotensin receptor blocker, Proton pump inhibitors, Parenteral nutrition drugs, Diabetes inspection, Glucose injection | |
| Antianginal drugs, Blood routine, 0.9 % sodium chloride injection, Diuretics, Biochemical routine, Basic care, Specific diet, Anticoagulant drug, Sedative and antianxietic drugs, Glucose injection, Consultation, Vitamins, Cephalosporins, Expectorants, ECG, Tuberculosis examination, Injection methods, Anesthesia, Urine routine, Glucose regulators, Xinqingning, Drug exchange, Skin preparation, β adrenergic receptor blockers, PTCA, Calcium channel blocker, Antiplatelet drug, Transferred, Blood collection, Electrolyte regulators, Troponin T, First-grade nursing, Blood pressure measurement, Antiarrhythmic drugs, Oxygen Inhalation, Lipid regulators, Second-grade nursing, Multifunctional monitors, Routine nursing, Discharge, Plasma and plasma substitutes, Angiotensin converting enzyme inhibitors, Coronary angiography, Thrombosis Inspection, Maren Runchang, Analysis of blood ion, Narcotic analgesics, Sterilized distilled water, Proton pump inhibitors, Seriously ill, Ganmao Qingre, Anti-diabetes drugs, Vasoactive drugs, Radionuclide examination, Local anesthetics, Enema, PH balance regulators, Digitalis glycosides, β-lactamase inhibitors, Drugs for bronchitis, Coagulation test, Parenteral nutrition drugs, Adrenocorticotropic hormone, Glycyrrhizae Mixture, Drugs for prostate diseases, Puncture, Peripheral vasodilators, Angiotensin receptor blocker, Drugs for cardiovascular diseases, Skin test, Calcium regulators, Tumor marker test, Gastrointestinal prokinetic agent, Adjuvant drugs for liver diseases, Occult blood test, CT, TEG, Stool routine | |
| α-adrenergic receptor blockers, Monitoring of ECG and blood oxygen, Ultrasound, X-Ray | |
| Renal function regulators, Intake and output | |
| 0.9 % sodium chloride injection, Antianginal drugs, Expectorants, Biochemical routine, Specific diet, Discharge, Blood routine, First-grade nursing, Tuberculosis examination, β adrenergic receptor blockers, Stool routine, Drug exchange, Electrolyte regulators, Sedative and antianxietic drugs, Second-grade nursing, Vasodilators, Drugs for cardiovascular diseases, Glucose regulators, Cephalosporins, Skin preparation, Blood collection, Thrombosis Inspection, Calcium channel blocker, Angiotensin converting enzyme inhibitors, Routine nursing, Maren Runchang, Anticoagulant drug, Transferred, Oxygen Inhalation, Urine routine, Sterilized distilled water, Plasma and plasma substitutes, Injection methods, Blood pressure measurement, Parenteral nutrition drugs, Multifunctional monitors, Vitamins, Analysis of blood ion, Vasoactive drugs, Coagulation test, Penicillins, Gastrointestinal antispasmodic drugs, Radionuclide examination, Adrenocorticotropic hormone, Diuretics, Enema, Troponin T, Narcotic analgesics, Lipid regulators, Local anesthetics, Blood transfusion, Consultation, Gastrointestinal prokinetic agent, Xinhuang, β-lactamase inhibitors, Glycyrrhizae Mixture, Diabetes inspection, Basic care, Ultrasound, Digitalis glycosides, Nitroglycerin membrane, Furacin, Calcium regulators, Puncture, PH balance regulators, Intake and output, Body temperature lowering, Intravenous anesthetics, Oral care, ECG, Antiepileptic and anticonvulsant drugs, Cerebral circulation regulators, Monitoring of ECG and blood oxygen, Antiplatelet drug, Anti-diabetes drugs, Proton pump inhibitors, Antiarrhythmic drugs, Occult blood test, X-Ray, Antipyretic and analgesic drugs, CT, Adjuvant drugs for liver diseases, Skin test | |
| Immunity test, Electrophysiological examination | |
Figure 10Examples of the changing trends of execution time for treatment interventions. (a) “Discharge” for low-risk patients, and (b) “Multifunctional monitors” for low-risk patients.
Figure 11Examples of treatment interventions that are considered to be rescheduled in the unstable angina treatment process protocol. (a) “Coronary Angiography” for low-risk patients, (b) “Stent implantation” for low-risk patients, and (c) “X-ray” for low-risk patients.